NAA Services for Anti-GBU4-5
Creative Biolabs is able to offer various high-quality NAA services with first-rate platforms and extensive experience in NAA (natural autoantibodies) detection. Now we can provide a wide range of anti-GBU4-5 antibodies marker services for disease diagnosis and therapeutic monitoring. Our experienced scientists will take part in every step of your program to facilitate your project development.
Background of Anti-GBU4-5 Antibodies
GBU4-5, identified by recombinant cDNA expression cloning (SEREX), encodes a DEAD-box domain (such as cancer-associated gene protein, CAGE), which has not been described as triggering autoantibody reaction until 2003. Autoantibody responses to different antigens that encode DEAD-box proteins have recently been described. These DEAD-box-containing proteins may be important in carcinogenic pathways. They play roles in RNA processing, ribosome assembly, spermatogenesis, embryogenesis, cell growth, and division. Moreover, they have immunogenicity and cancer specificity and may be used as diagnostic markers or potential targets in the course of immunotherapy for cancer. GBU4-5 acts as a tumor-associated antigen (TAA) in lung and other solid tumors, which can lead to the production of autoantibodies.
Fig.1 TAAs can elicit a B-lymphocyte response, inducing the production of autologous antibodies (autoantibodies). (Solassol, 2011)
The Role of Anti-GBU4-5 Antibodies in Lung Cancer
Lung cancer is a global clinical problem and a leading cause of cancer deaths, which can cause more than 1.2 million deaths each year. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer. More and more literatures describe the presence of a humoral immune response, in the form of autoantibodies, to TAA in lung and other solid tumors. Some individuals have autoantibodies before the onset of symptomatic cancer, which makes their identification particularly relevant to early detection. TAA can trigger T lymphocyte response, which kills tumor cells directly or indirectly by recruiting macrophages, polymorphonuclear cells, and natural killer cells. In addition, TAA can also induce B lymphocyte reaction and autoantibody production. As a kind of TAA, GBU4-5 autoantibody was detected in peripheral blood of SCLC and NSCLC patients. The results showed that GBU4-5 was significantly expressed in lung cancer. These observations indicate that GBU4-5 autoantibody can be used as a biomarker for lung cancer detection to a large extent.
What We Can Do about NAA?
NAA forms a network that protects the organism from external and internal dangers, but can also lead to autoimmune disease. With our first-class platforms and professional scientists, Creative Biolabs is capable to provide comprehensive NAA services, include NAA detection, NAA profiling, NAA affinity measurement, NAA epitope mapping, and paratope mapping. A wide range of NAA products is available for your choice.
Creative Biolabs specializes in NAA detection that is suitable for a number of immune diseases. In addition to lung cancer, other types of diseases, such as apoptosis, neurobiology, autoimmune diseases, cardiovascular diseases, infectious diseases and so on are also covered. Moreover, we offer customized solutions for our clients to meet every specific research requirement. Please contact us to experience our professional services.
Reference:
- Solassol, J.; et al. Clinical relevance of autoantibody detection in lung cancer. Journal of Thoracic Oncology. 2011, 6(5): 955-962.
Related Services:
- NAA Services for Anti-p53
- NAA Services for Anti-CAGE
- NAA Services for Anti-MUC1 Antibody
- NAA Services for Anti-HER2
- NAA Services for Anti-c-Myc Antibodies